If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
EMGALITY® (galcanezumab-gnlm): Aseptic Techniques During Supply Shortages
During medical supply shortages, Lilly encourages patients to contact their health care provider for assistance.
Patients should follow the guidance on good aseptic techniques, such as handwashing and use of alcohol wipes, as outlined in the galcanezumab “Instructions for Use.”1,2
Guidance During Medical Supply Shortages
The COVID-19 pandemic has caused widespread medical supply shortages, including alcohol swabs and bottles of 70% isopropyl alcohol.
During shortages, patients should contact their health care provider for suggested alternative aseptic measures.
Injection Site Preparation
As an alternative to the use of alcohol, the WHO recommends the use of soap and water for skin preparation and disinfection of injection sites.3
Enclosed Prescribing Information
EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1. EMGALITY [instructions for use, prefilled pen]. Eli Lilly and Company: Indianapolis, IN; 2019.
2. EMGALITY [instructions for use, prefilled syringe]. Eli Lilly and Company: Indianapolis, IN; 2019.
3. World Health Organization. WHO best practices for injections and related procedures toolkit. Published March 2010. Accessed March 23, 2020. https://apps.who.int/iris/bitstream/handle/10665/44298/9789241599252_eng.pdf?sequence=1
Glossary
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
WHO = World Health Organization
Date of Last Review: March 27, 2020